Drug Patents owned by Marinus

1. Drug name - ZTALMY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318714 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8618087 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US9056116 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8367651 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US9029355 MARINUS Solid ganaxolone compositions and methods for the making and use thereof
Nov, 2026

(3 years from now)

US8022054 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US7858609 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(3 years from now)

US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2027

Drugs and Companies using GANAXOLONE ingredient

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
50MG/ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in